Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors.
10.3779/j.issn.1009-3419.2019.10.12
- Author:
Jiaxin ZHOU
1
;
Qian WANG
1
;
Lian DUAN
2
;
Xiaoyan SI
3
;
Li ZHANG
4
;
Xiaowei LIU
5
;
Yue LI
6
;
Hanping WANG
3
;
Xiaoxiao GUO
7
;
Wen ZHANG
1
;
Li ZHANG
3
Author Information
1. Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
2. Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
3. Department of Respiratory medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
4. Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
5. Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
6. Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
7. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Immune-related adverse events;
Rheumatic disease;
Treatment
- From:
Chinese Journal of Lung Cancer
2019;22(10):671-675
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) have made remarkable breakthroughs in cancer treatment. However, the widely use of ICIs is associated with a spectrum of immune-related adverse events (irAEs). These adverse events can affect any organ system. In this article, we have made a systemic review about the clinical characteristics of rheumatic irAEs, and also summarized irAEs in patients with pre-exsiting rheumatic disease. We also focus on the management of rheumatic irAEs.
